Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
10 Setting up camp Shelters That Offer Both Excellence and Isolation - 2The most effective method to Pick A Trade-in vehicle Stage
- 3Best Exciting ride: Which One Rushes You the Most?
- 4Hundreds of Gazans evacuated from Strip for medical treatment - COGAT
- 5This Huge Ocean Beast Shifts Sharks’ Evolutionary Timeline
- Sustaining Public activity and Connections: Key Methodologies
- Novartis to build manufacturing hub in North Carolina, creating 700 jobs
- How to get rid of your Christmas tree — and the 1 thing to never, ever do with it
- the Kinds of Thailand: Decision in favor of Your Number one Thai Dish!
- Improving as a Cook: Culinary Experiences in the Kitchen
- 2024's Savvy Home Gadgets for an Associated Way of life
- Robyn returns to music with 'Dopamine,' her 1st single in 7 years: 'Came to save music once again'
- Make your choice for the sweet that transports you to its nation of beginning!
- The Response to Self-improvement: Embracing a Development Outlook
